2025
A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-report
Meda S, Stevens M, Boer E, Pittman B, Gueorguieva R, Huestis M, Pearlson G. A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-report. Journal Of Psychopharmacology 2025, 39: 364-372. PMID: 40077985, DOI: 10.1177/02698811251324379.Peer-Reviewed Original ResearchConceptsCannabis-induced impairmentBlood THC levelsDouble-blindCannabis useVaporized cannabisTHC levelsActual impairmentAcute doseWithin-subjectSelf-ReportSimulated driving testDrug effectsDriving impairmentPlacebo-ControlledImpairment indicatorsImpairmentCannabisAssessment daysEffect of doseParticipants' willingnessPost-doseTHCBehavioral metricsCar-followingParticipants
2009
Adolescent cannabis use increases risk for cocaine-induced paranoia
Kalayasiri R, Gelernter J, Farrer L, Weiss R, Brady K, Gueorguieva R, Kranzler HR, Malison RT. Adolescent cannabis use increases risk for cocaine-induced paranoia. Drug And Alcohol Dependence 2009, 107: 196-201. PMID: 19944543, PMCID: PMC2821949, DOI: 10.1016/j.drugalcdep.2009.10.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdolescent BehaviorAge FactorsAge of OnsetCannabisCatechol O-MethyltransferaseCocaine-Related DisordersFemaleGene FrequencyGenetic Predisposition to DiseaseHumansLogistic ModelsMaleParanoid DisordersPolymerase Chain ReactionPrevalencePsychiatric Status Rating ScalesRisk FactorsSeverity of Illness IndexSiblingsUnited StatesConceptsAdolescent onset cannabisEarly cannabis exposureCocaine-dependent individualsCocaine-induced paranoiaCannabis exposureRisk factorsCOMT genotypeSemi-Structured AssessmentCatechol-O-methyl transferase (COMT) geneCOMT Val158Met genotypeCannabis abuseIncrease riskPsychotic symptomsOnset interactionPsychotic disordersStimulant abuseDrug dependenceFamily-based studyLogistic regressionEarly exposureAdolescent cannabisCannabisGenetic factorsSignificant predictorsVal158Met genotype
2008
Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis
D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis. Neuropsychopharmacology 2008, 33: 2505-2516. PMID: 18185500, PMCID: PMC3799954, DOI: 10.1038/sj.npp.1301643.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmnesiaAttentionBrainDose-Response Relationship, DrugDouble-Blind MethodDronabinolDrug Administration ScheduleDrug ToleranceFemaleHallucinationsHallucinogensHumansHydrocortisoneMaleMarijuana AbuseMiddle AgedPerceptual DisordersProlactinPsychoses, Substance-InducedTachycardiaYoung AdultConceptsAmnestic effectsPerceptual alterationsDelta-9-TetrahydrocannabinolCannabis useSubjective effectsFrequent usersCannabisEffects of cannabinoidsIllicit substancesPsychotomimetic effectsEuphoric effectsHealthy controlsHealthy individualsMemoryImpairingPsychosisDose-related effectsIndividualsCortisolPsychotomimeticsAttentionPeopleUsersPlacebo-controlled studyEffect
2005
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
D’Souza D, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57: 594-608. PMID: 15780846, DOI: 10.1016/j.biopsych.2004.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAkathisia, Drug-InducedArousalCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolEndocrine SystemFemaleHumansInjections, IntravenousMaleMental RecallMiddle AgedMotor ActivityNeuropsychological TestsPerceptionPsychiatric Status Rating ScalesPsychotic DisordersPsychotropic DrugsSchizophreniaVerbal LearningConceptsSchizophrenia patientsAntipsychotic-treated schizophrenia patientsDelta-9-tetrahydrocannabinol effectsLong-term adverse eventsCognitive deficitsPlacebo-controlled studyDelta-9-THCTransient exacerbationAdverse eventsReceptor dysfunctionEndocrine effectsHealthy subjectsStudy participationPsychotic disordersPlasma prolactinSchizophrenia symptomsPatientsSchizophreniaCognitive effectsPerceptual alterationsDeficitsCannabisSubjectsAkathisiaExacerbation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply